International access
Cancer treatment in India
Large service volume with costs that are often lower than several other countries.
Orientation information, not an access guarantee
Facilities
Public-reference profiles
This list does not state partnership, quality, schedule, price, or international patient acceptance.
NO DATA
No facility profile has passed the public-reference model for this country yet.
Public registry
Recorded clinical trials
Available clinical trial counts are calculated from public registries and may change at any time. Counts shown on the page follow the most recent registry data imported.
NCT06875310Phase 3Combination regimen
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Lung Cancer | biomarker: KRAS | Immunotherapy, Targeted therapy, Chemotherapy
United States, Argentina, Australia +32349 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06875310Not verified
NCT06119581Phase 3Immunotherapy
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Lung Cancer | biomarker: KRAS, PD-L1 | Immunotherapy, Chemotherapy
United States, Australia, Austria +26415 registry sites
Why this appears: Appears because it is recorded for Lung Cancer, it mentions marker KRAS, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT06119581Not verified
NCT05519085Phase 3Targeted therapy
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Multiple Myeloma | Targeted therapy
United States, Argentina, Australia +26266 registry sites
Why this appears: Appears because it is recorded for Multiple Myeloma, the treatment category is Targeted therapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT05519085Not verified
NCT07221149Phase 2 / Phase 3Immunotherapy
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Stomach Cancer | Immunotherapy, Chemotherapy
United States, Argentina, Australia +18161 registry sites
Why this appears: Appears because it is recorded for Stomach Cancer, the treatment category is Immunotherapy.
What to verify: Acceptance of patients from outside the local country has not been verified.
- Registry
- Recruiting in registry
- Site
- Not verified
- International access
- Unknown
- Patient match
- Not assessed
Last checked 16 Oktober 2026Source ClinicalTrials.govNCT07221149Not verified
What needs confirmation
- • Visa, stay permit, and entry requirements for medical care must be checked through official government and embassy channels. TanyaKanker does not guarantee acceptance.
- • Service availability, written estimate, inclusions and exclusions.
- • Follow-up plan after returning to Indonesia.
Ask about access in India
Organise the case and questions without promises of acceptance, price, or treatment outcome.
After submission, a human navigator reviews your request and contacts you through your chosen channel. The WhatsApp message already includes this page context, so you do not need to explain from the beginning.
Clinical data is not requested in the form and is not sent to analytics. Do not send medical reports through WhatsApp or email; use the secure upload page. We do not promise eligibility or any treatment outcome.